Jiayang Yi
Lanlan Jia
Zhi Li- Department of Rheumatology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
IgG4-related disease (IgG4-RD) is a distinctive immune-mediated disorder characterized by multi-organ involvement, dense IgG4+ plasma cell infiltration, and storiform fibrosis. While pathogenesis has traditionally been attributed primarily to T helper type(Th) 2 cytokines (e.g., Interleukin(IL)-4/IL-10), this mechanism insufficiently accounts for the observed tissue destruction and progressive fibrosis. Emerging data highlight the extensive, oligoclonally expanded infiltration of CD4+ cytotoxic T lymphocytes (CTLs) deep within lesions. These cells possess dual cytotoxic and profibrotic properties. This review systematically elucidates the role of CD4+ CTLs as a distinct lineage and core effector population. We detail how these cells mediate the pathology linking chronic inflammation and fibrosis through direct cytotoxicity, secretion of profibrotic factors, and complex B-cell interactions. Finally, we assess the clinical potential of CD4+ CTLs as biomarkers of disease activity and as novel therapeutic targets.
1 Introduction
Immunoglobulin G4-Related Disease (IgG4-RD) is a recently recognized systemic fibroinflammatory disorder capable of affecting nearly every organ system (1–3). The classic histopathological triad consists of dense lymphoplasmacytic infiltration, storiform fibrosis, and obliterative phlebitis, often accompanied by significantly elevated IgG4 levels in affected tissues and/or serum (2, 4). Although glucocorticoid therapy is highly effective initially, up to 50% of patients experience relapse, and long-term disease progression frequently leads to irreversible organ fibrosis and functional impairment (5–7).
For a long time, the pathogenesis of IgG4-RD has been attributed to a T helper type(Th) 2 immune response paradigm, primarily based on the frequent allergic history reported by patients and the expression of Th2 cytokines (e.g., Interleukin(IL)-4, IL-10) within affected tissues (4, 8). However, this prevailing view faces increasingly severe challenges. Firstly, previous studies often failed to rigorously distinguish between the disease’s specific immune processes and coexisting allergic states. Secondly, a purely Th2 response poorly accounts for the significant tissue destruction, widespread collagen deposition, and defining fibrotic characteristics observed in IgG4-RD (4, 9). Consequently, there remains a critical knowledge gap concerning the core pathogenic mechanisms of IgG4-RD, necessitating the urgent identification of novel effector cells and molecular pathways.
Traditionally, CD4+ T cells are defined as helper cells, primarily responsible for coordinating the functions of other immune cells, such as B cells and CD8+ T cells. Nevertheless, a specialized subset possessing direct target cell killing capabilities—CD4+ Cytotoxic T Lymphocytes(CTLs)—is garnering attention, particularly in the contexts of chronic viral infections (e.g., Epstein-Barr virus, Cytomegalovirus, Human Immunodeficiency Virus) and tumor immunosurveillance (10). These cells highly express classical cytotoxic molecules, including granzymes and perforin, enabling them to efficiently induce target cell apoptosis in a Major Histocompatibility Complex(MHC) Class II-restricted manner (11–15). Importantly, the aberrant accumulation of CD4+ CTLs in fibrotic autoimmune diseases, such as Systemic Sclerosis and Sjögren’s Syndrome, suggests a significant profibrotic potential extending beyond their direct cytotoxic functions (4, 16–19).
Building upon this foundation, this review aims to integrate recent research findings to systematically demonstrate the mechanism by which CD4+ CTLs act as core effector cells driving the specific pathology of IgG4-RD, particularly focusing on tissue damage and fibrosis. We will thoroughly delineate their phenotypic characteristics, differentiation origins, specific pathogenic mechanisms, clinical relevance, and therapeutic implications. By attempting to transcend the conventional Th2 paradigm, we seek to provide an innovative theoretical framework for comprehensively understanding the pathogenesis of IgG4-RD and developing novel targeted therapeutic strategies.
2 Phenotypic landscape analysis of CD4+ cytotoxic T lymphocytes in IgG4-RD
The precise identification of CD4+ CTLs associated with IgG4-RD hinges on their unique combination of surface markers, transcription factors, and effector molecules. This characteristic molecular signature definitively distinguishes them from classical helper T subsets, including Th1, Th2, Th17, and follicular helper T cells (Tfh).
2.1 Core surface markers and transcriptional factors
Groundbreaking studies have designated Signaling Lymphocyte Activation Molecule Family Member 7 (SLAMF7, CD319) as a pivotal surface marker. Mattoo and colleagues were the first to identify the prominent clonal expansion of SLAMF7+ CD4+ T cells within both the peripheral blood and affected tissues of IgG4-RD patients (4). These findings were subsequently validated and expanded upon by independent cohorts (20–22), confirming SLAMF7 as a robust pathogenic signature. This observed oligoclonal expansion strongly implies an antigen-driven proliferation event originating from a limited pool of precursor cells (4, 20, 23). The expression of SLAMF7 shows a robust correlation with cytotoxicity, likely augmenting effector function via homophilic interactions that stabilize cell-to-cell contact (20, 24). Crucially, the concurrent enrichment of the chemokine receptor CX3CR1 and the terminal differentiation marker CD57 endows these SLAMF7+ CD4+ T cells with essential tissue-homing capabilities and characteristics indicative of an advanced effector state (25–28).
Regarding transcriptional regulation, CD4+ CTLs notably deviate from canonical helper subsets: they fail to express the lineage-defining master factors GATA3 (Th2) or Bcl6 (Tfh). Instead, they exhibit high expression of T-bet (TBX21) and Eomesodermin(Eomes), transcription factors intrinsically linked to cellular cytotoxicity and effector function (29, 30). Research indicates that T-bet and Eomes exert overlapping yet complementary roles in the induction of key effector molecules, including perforin, granzymes, and Interferon-γ(IFN-γ) (30, 31). Furthermore, the transcription factor Hobit is implicated in sustaining both the cytotoxic program and the tissue-resident phenotype of these cells (31, 32). This distinct and tightly regulated transcriptional network ultimately constitutes the molecular foundation driving the acquisition and long-term maintenance of the CD4+ CTLs’ lethal killing capacity and pronounced pro-inflammatory phenotype.
2.2 The effector molecular profile: cytotoxic granules and profibrotic cytokines
CD4+ CTLs in IgG4-RD are recognized as highly potent effector cells. They store and subsequently release classic cytotoxic granule components, including perforin, Granzyme A, and Granzyme B (4, 33, 34). Perforin functions by forming transmembrane channels on target cell membranes, which facilitates the entry of granzymes into the cytosol. Granzymes then directly initiate target cell apoptosis through the cleavage of critical substrates, such as caspases (14, 35).
Of greater pathological significance is the distinct cytokine profile secreted by these cells. Unlike the typical Th2 signature, which primarily features IL-4, IL-5, and IL-13, CD4+ CTLs predominantly generate IFN-γ, IL-1β, and TGF-β1 (4, 36–38). It is this specific molecular convergence that underpins their functional duality, equipping them to wield destructive inflammatory power while concurrently orchestrating the machinery of fibrosis. As a potent pro-inflammatory mediator, IFN-γ activates macrophages, thereby exacerbating the local inflammatory response (39). Conversely, TGF-β1 is widely recognized as one of the most powerful pro-fibrotic factors. It directly activates fibroblasts, promoting their transdifferentiation into myofibroblasts and resulting in the excessive deposition of the Extracellular Matrix (40–42). Moreover, IL-1β further amplifies inflammatory signals and acts synergistically with TGF-β to accelerate the progression of fibrosis (43, 44). Collectively, these data suggest that CD4+ CTLs function as a mobilized fibrotic driver unit, capable of precisely delivering both cellular cytotoxic and pro-fibrotic signals directly into the pathological lesion.
2.3 Single-cell omics evidence
Single-cell RNA sequencing (scRNA-seq) offers robust evidence for the precise identification of CD4+ CTLs within complex tissue microenvironments. Maehara et al. analyzed scRNA-seq data from affected IgG4-RD tissues (pancreas, kidney, salivary glands) (45, 46). This analysis revealed that the most pronounced clonal expansion among tissue-infiltrating T cells belonged to CD4+ T cells characterized by a cytotoxic gene signature (high expression of *Granzyme A*, *Granzyme B*, *PRF1*, *IFNG*, and *SLAMF7*). Collectively, these transcriptomic data confirm that CD4+ CTLs are the dominant and clonally expanded T cell population in IgG4-RD lesions, displacing traditional Th2 or other helper subsets.
3 Ontogeny and differentiation of CD4+ CTLs
The prominent oligoclonal expansion of CD4+ CTLs observed in IgG4-RD robustly indicates that their differentiation and subsequent proliferation are driven by specific antigenic stimulation (34).
3.1 The antigen-driven hypothesis
T-cell receptor (TCR) sequencing analyses have demonstrated that CD4+ CTLs infiltrating affected tissues possess a highly restricted TCR repertoire, where a limited number of clones achieve clonal dominance (4, 47). This phenomenon suggests that specific peptide-MHC Class II complexes may persistently activate corresponding naïve or memory CD4+ T cells, thereby driving their selective expansion and subsequent differentiation into a cytotoxic effector phenotype.
Although the specific antigens driving IgG4-RD remain unidentified, the “chronic, repetitive antigenic stimulation” model constitutes the central mechanistic hypothesis explaining the genesis of CD4+ CTLs. Potential sources for these antigens include microbial agents (such as viruses), autoantigens, and neoantigens exposed following tissue injury.
3.2 Potential for viral induction
Given the critical role of CD4+ CTLs in controlling latent infections such as Epstein-Barr virus and Cytomegalovirus, researchers have hypothesized that the reactivation or persistent antigenic exposure from these viruses may serve as a potential trigger for IgG4-RD (10).
Studies confirm that primary Epstein-Barr virus infection induces robust, antigen-specific CD4+ CTL responses (48, 49). In the context of chronic infection, sustained antigenic stimulation is known to propel CD4+ T cells toward a terminally differentiated cytotoxic phenotype (48, 50). However, it is crucial to acknowledge that direct evidence establishing a causal link between specific viral infections and IgG4-RD remains elusive. While the “hit-and-run” hypothesis or persistent viral antigen exposure is biologically plausible, no specific viral genome has been consistently isolated from IgG4-RD lesions across studies. Thus, the viral etiology currently serves as a theoretical framework rather than a proven mechanism.
3.3 Shaping the cytokine environment
A distinct cytokine milieu is indispensable for the differentiation of CD4+ T cells into the CTL phenotype. Cytokines such as IL-2, IL-12, and IL-15 strongly promote the expression of the crucial transcription factors T-bet and Eomes, concomitantly upregulating the production of key cytotoxic molecules like granzyme and perforin (51–54).
Furthermore, given that IL-21 has been demonstrated to enhance the cytotoxic function of CD8+ T cells, its potential role in the differentiation pathway of CD4+ CTLs warrants focused investigation (55, 56). Although direct evidence of IL-21 driving CD4+ CTL differentiation specifically within IgG4-RD tissues is still emerging, generally elevated IL-21 levels in IgG4-RD (typically associated with Tfh cells) could theoretically contribute to this process. In the inflammatory microenvironment characteristic of IgG4-RD, these cytokines—secreted by infiltrating plasma cells, B cells, and macrophages—likely synergize to form a unique “cytokine cocktail” that specifically drives the differentiation of naïve or central memory CD4+ T cells into CD4+ CTLs (57–59).
4 Core pathogenic mechanisms mediated by CD4+ cytotoxic T lymphocytes in IgG4-RD
CD4+ CTLs are pivotal to the pathogenesis of IgG4-RD. These cells employ multiple synergistic pathways, directly orchestrating the hallmark histopathological changes characteristic of this fibroinflammatory disorder (Figure 1).
Figure 1. Schematic diagram illustrating the central driving role of CD4+ CTLs in the pathogenesis of IgG4-RD. Centrally positioned SLAMF7+ CD4+ CTLs drive pathological progression through three primary pathways: (1) Cytotoxic pathway (left): Induce apoptosis in MHC II-expressing epithelial/endothelial cells by releasing perforin, granzyme B, and FasL-Fas interaction, thereby releasing DAMPs to exacerbate inflammation; (2) Fibrosis pathway (bottom): Secretion of TGF-β1 and IL-1β activates fibroblasts; concurrently, extracellular granzyme A directly induces myofibroblast transformation and Dense Fibrosis by cleaving the PAR-1 receptor; (3) Inflammatory Feedback Loop (right): Interacts with IgG4+ B cells/plasma cells via MHC II for antigen presentation, forming a sustained positive feedback loop of activation, and secretes IFN-γ to activate macrophages.
4.1 Direct cytotoxicity and tissue injury
CD4+ CTLs primarily execute target cell lysis through two canonical pathways: the perforin-granzyme pathway and the Fas Ligand(FasL)-Fas pathway. Target cells typically express MHC Class II molecules. In affected tissues, such as salivary glands, pancreatic ducts, and bile ducts, inflammatory stimuli induce the upregulation of MHC Class II on epithelial and endothelial cells, converting these cells into key targets for CD4+ CTL attack (60–62). The release of perforin and Granzyme B directly triggers programmed cell death (apoptosis) in the target cells (35, 63). Concurrently, the interaction between FasL expressed on CD4+ CTLs and Fas on the target cell surface activates the canonical death receptor-mediated apoptotic cascade (52, 64). Of note, environmental factors such as oxidative stress can significantly enhance the susceptibility of endothelial cells to Fas-mediated apoptosis (64, 65).
This direct cellular killing is the initiating event for ensuing tissue injury and structural disruption. Apoptotic cells subsequently release abundant intracellular antigens and damage-associated molecular pattern (66), thereby amplifying the localized inflammatory cycle and providing the requisite initiating signals for subsequent tissue remodeling and fibrosis (67).
4.2 Critical mechanisms driving fibrosis
The induction of fibrosis stands out as one of the most critical and high-impact pathogenic contributions of CD4+ CTLs to the immunopathology of IgG4-RD. Their pro-fibrotic effects are mediated both through soluble cytokines (68) and via direct, apoptosis-independent mechanisms (69).
Cytokine-mediated fibrosis centers on TGF-β1 secreted by CD4+ CTLs, which critically drives fibroblast activation and subsequent Extracellular Matrix synthesis (40). This effect is amplified by IL-1β, which acts synergistically with TGF-β to potentiate pro-fibrotic gene expression. Crucially, these CD4+ CTLs concurrently release IFN-γ, a factor largely deemed anti-fibrotic due to its capacity to suppress TGF-β signaling and fibroblast collagen synthesis (40, 70, 71). Therefore, IgG4-RD-associated fibrosis evolves within a complex microenvironment defined by this imbalance between pro- and anti-fibrotic factors; yet, the robust pro-fibrotic signaling provided by the CD4+ CTLs ultimately prevails.
Recent studies have demonstrated that Granzyme A possesses an apoptosis-independent profibrotic function. Extracellular Granzyme A cleaves crucial Extracellular Matrix components, such as Type IV collagen and fibronectin, thereby compromising basement membrane integrity (72, 73). Crucially, Granzyme A directly activates fibroblasts by proteolytically cleaving and activating protease-activated receptor-1 (PAR-1) (74, 75). PAR-1 activation, a G protein-coupled receptor signaling event, subsequently initiates intracellular calcium mobilization, RhoA activation, and the MAPK signaling cascade. These downstream events culminate in heightened fibroblast proliferation, migration, and augmented collagen synthesis (75, 76). This mechanism effectively couples the cytotoxic effector functions of CD4+ CTLs with their capacity for tissue remodeling, allowing for a devastating “dual-mode” progression of the disease.
While CD4+ CTLs provide a robust explanation for the intensity of fibrosis via TGF-β1, IL-1β, and Granzyme A-mediated matrix remodeling, the mechanism driving the specific “storiform” (cartwheel-like) architectural pattern remains an intriguing open question. The storiform pattern likely results from complex spatial interactions between activated myofibroblasts, inflammatory cells, and the physical forces within the edematous tissue, rather than cytokine signaling alone. Whether CD4+ CTLs influence this spatial arrangement through specific cell-cell contact or localized matrix cleavage requires further high-resolution spatial transcriptomic analysis.
4.3 The T-B cell interaction axis
A critical and intricate interplay exists between CD4+ CTLs and the B cell/plasma cell lineage, establishing a central axis in IgG4-RD immunopathology.
While some observations note low-level expression of Bcl6 or CXCR5 on CD4+ CTLs, hinting at a potential Tfh-like function (77), the prevailing consensus classifies this population as a distinct subset. Its defining characteristic remains cytotoxicity rather than canonical T-helper activity (77, 78). Consequently, these cells may not directly dictate IgG4 class switching but instead modulate B cell activation and differentiation indirectly by orchestrating a specific inflammatory milieu.
A widely accepted model posits that activated B cells and plasma cells function as highly efficient antigen-presenting cells (APCs), sustaining the activation and clonal expansion of CD4+ CTLs through continuous antigen presentation via MHC Class II molecules (10, 50, 79, 80). This interaction establishes a potent positive feedback loop: activated CD4+ CTLs drive inflammation and subsequent tissue damage, which, in turn, releases a greater antigenic burden. B cells subsequently internalize, process, and present these liberated antigens, thereby perpetuating the stimulation of the CD4+ T cell population. Crucially, this mechanism elegantly accounts for the pronounced therapeutic efficacy of the B-cell-depleting agent Rituximab. Rituximab achieves clinical remission by not only eliminating antibody-producing cells, but also by interrupting this T-B cell axis, which leads to a concomitant decline in CD4+ CTL populations (59, 81–84).
5 Clinical relevance and potential biomarker utility
Beyond their clear pathological significance, the cellular frequency and functional status of CD4+ CTLs correlate strongly with various clinical parameters, establishing them as highly promising candidates for effective biomarkers. Consistent findings across numerous studies demonstrate a significant positive correlation between the frequency of CD4+ CTLs—both in the peripheral circulation and within affected tissues—and the degree of disease activity. Specifically, CD4+ CTL counts are closely associated with serum IgG4 levels, the overall burden of affected organs, and established clinical disease activity scores (4, 69).
Crucially, existing evidence further suggests a strong correlation between the degree of CD4+ CTL infiltration in lesional tissue and the severity of irreversible tissue fibrosis (69, 85). This critical association suggests that monitoring CD4+ CTLs could serve multiple clinical purposes: assessing disease activity, predicting the risk of potential relapse, and tracking the progression of organ fibrosis. Such monitoring could be achieved through detailed analysis of biopsy samples or non-invasively via flow cytometry for specific subsets, such as the SLAMF7+CD4+ T cell population. Compared to reliance solely on serum IgG4 levels, which possess inherent limitations regarding specificity and sensitivity, CD4+ CTLs offer a potentially more direct and precise metric for quantifying the intensity of the underlying pathogenic immune response.
6 Therapeutic implications: targeting CD4+ CTLs
A thorough comprehension of the pivotal role played by CD4+ CTLs in pathogenesis is crucial. This understanding not only aids in re-evaluating the mechanisms of action for established therapies but also illuminates promising avenues for the development of innovative treatments (Table 1).
Table 1. Overview of current and emerging therapeutic strategies targeting CD4+ CTLs in IgG4-RD.
6.1 Re-evaluation of existing therapeutic mechanisms
6.1.1 Glucocorticoids
Glucocorticoids, which exert their therapeutic effects through the broad suppression of immune cell activity and cytokine production, predictably inhibit activated CD4+ CTLs.
6.1.2 Rituximab
The clinical success of Rituximab is often attributed to the depletion of B cells and plasma cells. However, a more fundamental mechanism may involve the effective disruption of the critical pathogenic axis: B cell-mediated antigen presentation leading to CD4+ CTL activation. This disruption subsequently induces the reduction in CD4+ CTL counts and functional inactivation (79, 86–88). Consequently, this refined mechanistic view provides a more precise immunological rationale for the application of Rituximab in IgG4-RD.
6.2 Potential novel therapeutic targets
6.2.1 Elotuzumab (anti-SLAMF7 monoclonal antibody)
Targeting Signaling Lymphocyte Activation Molecule Family Member 7 (SLAMF7) represents a highly forward-looking therapeutic strategy. Elotuzumab is a humanized monoclonal antibody currently approved for treating multiple myeloma. Its mechanism of action involves augmenting natural killer cell-mediated antibody-dependent cell cytotoxicity and impeding the homotypic interactions of SLAMF7 (89–93).
Crucially, SLAMF7 has been identified as a signature marker for pathogenic CD4+ CTLs in IgG4-RD, where its interactions are hypothesized to promote cellular activation and subsequent tissue infiltration (20, 24). Theoretically, therefore, Elotuzumab could achieve therapeutic efficacy in IgG4-RD, especially for refractory or relapsing cases, by either directly clearing SLAMF7-positive CD4+ CTLs or functionally suppressing them.
6.2.2 Abatacept
Abatacept is a synthetic fusion protein designed to mimic Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4). It acts by binding competitively to CD80/CD86 molecules on antigen-presenting cells (APCs), thereby preventing the essential co-stimulatory interaction with the T cell receptor CD28 (94, 95). This mechanism effectively blocks the T cell co-stimulatory signal (Signal 2), a critical requirement for T cell activation, including that of CD4+ CTLs. Specifically targeting co-stimulatory signaling is posited as a potentially potent inhibitory strategy against the clonal expansion of CD4+ CTLs, which is often sustained by chronic antigenic stimulation.
6.2.3 Janus kinase inhibitors
The activation and effector function of CD4+ CTLs are highly contingent upon cytokine-driven signal transduction. Key examples include IFN-γ signaling through the JAK1/JAK2-STAT1 pathway and IL-2 via the JAK1/JAK3-STAT5 pathway. JAK inhibitors (e.g., Tofacitinib, Baricitinib) offer a means to broadly disrupt these downstream signaling cascades, consequently suppressing the activation, proliferation, and effector functions of CD4+ CTLs (96, 97). This strategy offers a distinct potential therapeutic avenue for mitigating CD4+ CTL-mediated pathology.
7 Conclusion and future directions
Positioning CD4+ CTLs at the core of IgG4-RD pathogenesis offers a persuasive framework that transcends the traditional Th2 paradigm to provide a more robust explanation for the disease’s complexity. By seamlessly integrating direct tissue cytotoxicity, the release of potent pro-fibrotic factors, and pathogenic B-cell crosstalk, this unique subset precisely mirrors the hallmark pathological features of IgG4-RD characterized by the simultaneous presence of inflammatory destruction and significant fibrosis. Indeed, the role of CD4+ CTLs is now well-established, with evidence ranging from the identification of clonally expanded phenotypes and the elucidation of molecular mechanisms driving fibrosis to their correlation with clinical activity and the definition of potential therapeutic targets.
Nevertheless, further advancement necessitates resolving several critical scientific inquiries, beginning with the elucidation of antigen specificity to determine whether the driving force stems from common environmental microbes or tissue-specific autoantigens, which remains a fundamental issue in understanding etiology. Concurrently, research must define the precise differentiation trajectories using in vivo localization techniques to identify the microenvironmental signals instructing this phenotype. Furthermore, it is crucial to assess whether functional or phenotypic heterogeneity across organs accounts for the diverse clinical presentations of IgG4-RD. Finally, developing translational interventions requires a delicate balance between ablating pathogenic CD4+ CTLs and preserving protective immunity, a context in which clinical trials focusing on targets such as SLAMF7 represent pivotal steps toward validating this theory and ultimately delivering highly effective and personalized therapeutic regimens.
Author contributions
JY: Writing – review & editing, Writing – original draft. LJ: Writing – review & editing. TM: Writing – review & editing, Investigation. ZL: Writing – original draft, Writing – review & editing, Investigation.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Stone JH, Zen Y, and Deshpande V. IgG4-related disease. N Engl J Med. (2012) 366:539–51. doi: 10.1056/NEJMra1104650
2. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol Off J U S Can Acad Pathol Inc. (2012) 25:1181–92. doi: 10.1038/modpathol.2012.72
3. Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire J-F, et al. The 2019 american college of rheumatology/european league against rheumatism classification criteria for igG4-related disease. Arthritis Rheumatol Hoboken NJ. (2020) 72:7–19. doi: 10.1002/art.41120
4. Mattoo H, Stone JH, and Pillai S. Clonally expanded cytotoxic CD4+ T cells and the pathogenesis of IgG4-related disease. Autoimmunity. (2017) 50:19–24. doi: 10.1080/08916934.2017.1280029
5. Cai S, Chen Y, Lin S, Ye C, Zheng F, and Dong L. Multiple processes may involve in the igG4-RD pathogenesis: an integrative study via proteomic and transcriptomic analysis. Front Immunol. (2020) 11:1795. doi: 10.3389/fimmu.2020.01795
6. Kanda M, Kamekura R, Sugawara M, Nagahata K, Suzuki C, Takano K, et al. IgG4-related disease administered dupilumab: case series and review of the literature. RMD Open. (2023) 9:e003026. doi: 10.1136/rmdopen-2023-003026
7. Zongfei J, Lingli C, Ying S, Lingying M, Lijuan Z, Dongmei L, et al. Clinical and pathological predictors of relapse in IgG4-related disease. Arthritis Res Ther. (2022) 24:106. doi: 10.1186/s13075-022-02792-z
8. Muller R, Ebbo M, Habert P, Daniel L, Briantais A, Chanez P, et al. Thoracic manifestations of IgG4-related disease. Respirol Carlton Vic. (2023) 28:120–31. doi: 10.1111/resp.14422
9. Hsieh S-C, Shen C-Y, Liao H-T, Chen M-H, Wu C-H, Li K-J, et al. The cellular and molecular bases of allergy, inflammation and tissue fibrosis in patients with igG4-related disease. Int J Mol Sci. (2020) 21:5082. doi: 10.3390/ijms21145082
10. Malyshkina A, Brüggemann A, Paschen A, and Dittmer U. Cytotoxic CD4+ T cells in chronic viral infections and cancer. Front Immunol. (2023) 14:1271236. doi: 10.3389/fimmu.2023.1271236
11. Shah BA, Holden JA, Lenzo JC, Hadjigol S, and O’Brien-Simpson NM. Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer. NPJ Vaccines. (2025) 10:68. doi: 10.1038/s41541-025-01118-9
12. Isser A, Silver AB, Pruitt HC, Mass M, Elias EH, Aihara G, et al. Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy. Nat Commun. (2022) 13:6086. doi: 10.1038/s41467-022-33597-y
13. Wirth M, Brenner W, and Krämer OH. Boosting T cell immunity against cytomegalovirus: a potential strategy combating human aging and age-related diseases. Signal Transduct Target Ther. (2023) 8:325. doi: 10.1038/s41392-023-01590-6
14. Hay ZLZ and Slansky JE. Granzymes: the molecular executors of immune-mediated cytotoxicity. Int J Mol Sci. (2022) 23:1833. doi: 10.3390/ijms23031833
15. Tang XX, Shimada H, and Ikegaki N. Clinical relevance of CD4 cytotoxic T cells in high-risk neuroblastoma. Front Immunol. (2021) 12:650427. doi: 10.3389/fimmu.2021.650427
16. Dai B, Ding L, Zhao L, Zhu H, and Luo H. Contributions of immune cells and stromal cells to the pathogenesis of systemic sclerosis: recent insights. Front Pharmacol. (2022) 13:826839. doi: 10.3389/fphar.2022.826839
17. Papadimitriou T-I, van Caam A, van der Kraan PM, and Thurlings RM. Therapeutic options for systemic sclerosis: current and future perspectives in tackling immune-mediated fibrosis. Biomedicines. (2022) 10:316. doi: 10.3390/biomedicines10020316
18. Zhang M, Chong KK, Chen Z-Y, Guo H, Liu Y-F, Kang Y-Y, et al. Rapamycin improves Graves’ orbitopathy by suppressing CD4+ cytotoxic T lymphocytes. JCI Insight. (2023) 8:e160377. doi: 10.1172/jci.insight.160377
19. Sisto M and Lisi S. Immune and non-immune inflammatory cells involved in autoimmune fibrosis: new discoveries. J Clin Med. (2023) 12:3801. doi: 10.3390/jcm12113801
20. Lingel H, Fischer L, Remstedt S, Kuropka B, Philipsen L, Han I, et al. SLAMF7 (CD319) on activated CD8+ T cells transduces environmental cues to initiate cytotoxic effector cell responses. Cell Death Differ. (2025) 32:561–72. doi: 10.1038/s41418-024-01399-y
21. Rovati L, Kaneko N, Pedica F, Monno A, Maehara T, Perugino C, et al. Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease. Rheumatol Oxf Engl. (2021) 60:4929–41. doi: 10.1093/rheumatology/keab096
22. Hara A, Watanabe T, Minaga K, Yoshikawa T, Kamata K, and Kudo M. Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease. World J Gastroenterol. (2021) 27:2257–69. doi: 10.3748/wjg.v27.i19.2257
23. Akiyama M, Suzuki K, Yoshimoto K, Yasuoka H, Kaneko Y, and Takeuchi T. Peripheral TIGIT+ T follicular helper cells that produce high levels of interleukin-21 via OX40 represent disease activity in igG4-related disease. Front Immunol. (2021) 12:651357. doi: 10.3389/fimmu.2021.651357
24. Cachot A, Bilous M, Liu Y-C, Li X, Saillard M, Cenerenti M, et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv. (2021) 7:eabe3348. doi: 10.1126/sciadv.abe3348
25. Phetsouphanh C, Aldridge D, Marchi E, Munier CML, Meyerowitz J, Murray L, et al. Maintenance of functional CD57+ Cytolytic CD4+ T cells in HIV+ Elite controllers. Front Immunol. (2019) 10:1844. doi: 10.3389/fimmu.2019.01844
26. Kared H, Tan C, Narang V, Tan SW, Xian CH, Wei ATS, et al. SLAMF7 defines subsets of human effector CD8 T cells. Sci Rep. (2024) 14:30779. doi: 10.1038/s41598-024-80971-5
27. Wanjalla CN, Gabriel CL, Fuseini H, Bailin SS, Mashayekhi M, Simmons J, et al. CD4+ T cells expressing CX3CR1, GPR56, with variable CD57 are associated with cardiometabolic diseases in persons with HIV. Front Immunol. (2023) 14:1099356. doi: 10.3389/fimmu.2023.1099356
28. Autaa G, Korenkov D, van Beek J, Pellegrin I, Parfait B, van Baarle D, et al. Re-evaluating CD57 as a marker of T cell senescence: implications for immune ageing and differentiation. Immun Ageing A. (2025) 22:47. doi: 10.1186/s12979-025-00542-8
29. Dejean AS, Joulia E, and Walzer T. The role of Eomes in human CD4 T cell differentiation: A question of context. Eur J Immunol. (2019) 49:38–41. doi: 10.1002/eji.201848000
30. Thelen B, Schipperges V, Knörlein P, Hummel JF, Arnold F, Kupferschmid L, et al. Eomes is sufficient to regulate IL-10 expression and cytotoxic effector molecules in murine CD4+ T cells. Front Immunol. (2023) 14:1058267. doi: 10.3389/fimmu.2023.1058267
31. Peng S, Lin A, Jiang A, Zhang C, Zhang J, Cheng Q, et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol Cancer. (2024) 23:58. doi: 10.1186/s12943-024-01972-6
32. Venkatesh H, Tracy SI, and Farrar MA. Cytotoxic CD4 T cells in the mucosa and in cancer. Front Immunol. (2023) 14:1233261. doi: 10.3389/fimmu.2023.1233261
33. Honda F, Tsuboi H, Ono Y, Abe S, Takahashi H, Ito K, et al. Pathogenic roles and therapeutic potential of the CCL8-CCR8 axis in a murine model of IgG4-related sialadenitis. Arthritis Res Ther. (2021) 23:214. doi: 10.1186/s13075-021-02597-6
34. Motta RV and Culver EL. IgG4 autoantibodies and autoantigens in the context of IgG4-autoimmune disease and IgG4-related disease. Front Immunol. (2024) 15:1272084. doi: 10.3389/fimmu.2024.1272084
35. Tuomela K, Ambrose AR, and Davis DM. Escaping death: how cancer cells and infected cells resist cell-mediated cytotoxicity. Front Immunol. (2022) 13:867098. doi: 10.3389/fimmu.2022.867098
36. Yang Y, Wang C, Shi L, Yang S, Liu Y, Luo J, et al. Clinical characteristics and CD4+ T cell subsets in igG4-related disease. Front Immunol. (2022) 13:825386. doi: 10.3389/fimmu.2022.825386
37. Hoeks C, Vanheusden M, Peeters LM, Stinissen P, Broux B, and Hellings N. Treg-resistant cytotoxic CD4+ T cells dictate T helper cells in their vicinity: TH17 skewing and modulation of proliferation. Int J Mol Sci. (2021) 22:5660. doi: 10.3390/ijms22115660
38. Pereira MVA, Galvani RG, Gonçalves-Silva T, de Vasconcelo ZFM, and Bonomo A. Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer. Front Immunol. (2024) 15:1379376. doi: 10.3389/fimmu.2024.1379376
39. Ha J-G and Cho H-J. Unraveling the role of epithelial cells in the development of chronic rhinosinusitis. Int J Mol Sci. (2023) 24:14229. doi: 10.3390/ijms241814229
40. Ding L, Yang J, Zhang C, Zhang X, and Gao P. Neutrophils modulate fibrogenesis in chronic pulmonary diseases. Front Med. (2021) 8:616200. doi: 10.3389/fmed.2021.616200
41. Gubert F, da Silva JS, Vasques JF, de Jesus Gonçalves RG, Martins RS, de Sá MPL, et al. Mesenchymal stem cells therapies on fibrotic heart diseases. Int J Mol Sci. (2021) 22:7447. doi: 10.3390/ijms22147447
42. Ye Z and Hu Y. TGF−β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review). Int J Mol Med. (2021) 48:132. doi: 10.3892/ijmm.2021.4965
43. Xin S, Liu X, He C, Gao H, Wang B, Hua R, et al. Inflammation accelerating intestinal fibrosis: from mechanism to clinic. Eur J Med Res. (2024) 29:335. doi: 10.1186/s40001-024-01932-2
44. Panagiotidis G-D, Vasquez-Pacheco E, Chu X, Seeger W, El Agha E, Bellusci S, et al. Revisiting pulmonary fibrosis: inflammatory dynamics of the lipofibroblast-to-inflammatory lipofibroblast-to-activated myofibroblast reversible switch. Front Immunol. (2025) 16:1609509. doi: 10.3389/fimmu.2025.1609509
45. Maehara T, Koga R, and Nakamura S. Immune dysregulation in immunoglobulin G4-related disease. Jpn Dent Sci Rev. (2023) 59:1–7. doi: 10.1016/j.jdsr.2022.12.002
46. Kaneko N, Chen H, Perugino CA, Maehara T, Munemura R, Yokomizo S, et al. Cytotoxic CD8+ T cells may be drivers of tissue destruction in Sjögren’s syndrome. Sci Rep. (2022) 12:15427. doi: 10.1038/s41598-022-19397-w
47. Patil VS, Madrigal A, Schmiedel BJ, Clarke J, O’Rourke P, de Silva AD, et al. Precursors of human CD4+ cytotoxic T lymphocytes identified by single-cell transcriptome analysis. Sci Immunol. (2018) 3:eaan8664. doi: 10.1126/sciimmunol.aan8664
48. Meckiff BJ, Ladell K, McLaren JE, Ryan GB, Leese AM, James EA, et al. Primary EBV infection induces an acute wave of activated antigen-specific cytotoxic CD4+ T cells. J Immunol Baltim Md. (2019) 1950:203. doi: 10.4049/jimmunol.1900377
49. Amarillo ME, Moyano A, Ferressini Gerpe N, De Matteo E, Preciado MV, and Chabay P. Tonsillar cytotoxic CD4 T cells are involved in the control of EBV primary infection in children. Sci Rep. (2024) 14:2135. doi: 10.1038/s41598-024-592666-4
50. Ruiz-Pablos M. CD4+ Cytotoxic T cells involved in the development of EBV-associated diseases. Pathog Basel Switz. (2022) 11:831. doi: 10.3390/pathogens11080831
51. Aehnlich P, Carnaz Simões AM, Skadborg SK, Holmen Olofsson G, and Thor Straten P. Expansion with IL-15 increases cytotoxicity of Vγ9Vδ2 T cells and is associated with higher levels of cytotoxic molecules and T-bet. Front Immunol. (2020) 11:1868. doi: 10.3389/fimmu.2020.01868
52. Tian L, Zhou W, Wu X, Hu Z, Qiu L, Zhang H, et al. CTLs: Killers of intracellular bacteria. Front Cell Infect Microbiol. (2022) 12:967679. doi: 10.3389/fcimb.2022.967679
53. Kiekens L, Van Loocke W, Taveirne S, Wahlen S, Persyn E, Van Ammel E, et al. T-BET and EOMES accelerate and enhance functional differentiation of human natural killer cells. Front Immunol. (2021) 12:732511. doi: 10.3389/fimmu.2021.732511
54. Mirlekar B and Pylayeva-Gupta Y. IL-12 family cytokines in cancer and immunotherapy. Cancers. (2021) 13:167. doi: 10.3390/cancers13020167
55. Xue D, Hsu E, Fu Y-X, and Peng H. Next-generation cytokines for cancer immunotherapy. Antib Ther. (2021) 4:123–33. doi: 10.1093/abt/tbab014
56. Wei F, Cheng X-X, Xue JZ, and Xue S-A. Emerging strategies in TCR-engineered T cells. Front Immunol. (2022) 13:850358. doi: 10.3389/fimmu.2022.850358
57. Chen Y, Cai S, Dong L, and Umehara H. Update on classification, diagnosis, and management of immunoglobulin G4-related disease. Chin Med J (Engl). (2022) 135:381–92. doi: 10.1097/CM9.0000000000001891
58. Liu J, Yin W, Westerberg LS, Lee P, Gong Q, Chen Y, et al. Immune dysregulation in igG4-related disease. Front Immunol. (2021) 12:738540. doi: 10.3389/fimmu.2021.738540
59. Michailidou D, Schwartz DM, Mustelin T, and Hughes GC. Allergic aspects of igG4-related disease: implications for pathogenesis and therapy. Front Immunol. (2021) 12:693192. doi: 10.3389/fimmu.2021.693192
60. Yura Y and Hamada M. Outline of salivary gland pathogenesis of sjögren’s syndrome and current therapeutic approaches. Int J Mol Sci. (2023) 24:11179. doi: 10.3390/ijms241311179
61. Heuberger CE, Janney A, Ilott N, Bertocchi A, Pott S, Gu Y, et al. MHC class II antigen presentation by intestinal epithelial cells fine-tunes bacteria-reactive CD4 T-cell responses. Mucosal Immunol. (2024) 17:416–30. doi: 10.1016/j.mucimm.2023.05.001
62. Moniruzzaman M, Rahman MA, Wang R, Wong KY, Chen AC-H, Mueller A, et al. Interleukin-22 suppresses major histocompatibility complex II in mucosal epithelial cells. J Exp Med. (2023) 220:e20230106. doi: 10.1084/jem.20230106
63. Thompson R and Cao X. Reassessing granzyme B: unveiling perforin-independent versatility in immune responses and therapeutic potentials. Front Immunol. (2024) 15:1392535. doi: 10.3389/fimmu.2024.1392535
64. Kural MH, Djakbarova U, Cakir B, Tanaka Y, Chan ET, Arteaga Muniz VI, et al. Mechano-inhibition of endocytosis sensitizes cancer cells to Fas-induced Apoptosis. Cell Death Dis. (2024) 15:440. doi: 10.1038/s41419-024-06822-3
65. Fujii J, Homma T, and Osaki T. Superoxide radicals in the execution of cell death. Antioxid Basel Switz. (2022) 11:501. doi: 10.3390/antiox11030501
66. Murao A, Aziz M, Wang H, Brenner M, and Wang P. Release mechanisms of major DAMPs. Apoptosis Int J Program Cell Death. (2021) 26:152–62. doi: 10.1007/s10495-021-01663-3
67. Liu X, Lu F, and Chen X. Examination of the role of necroptotic damage-associated molecular patterns in tissue fibrosis. Front Immunol. (2022) 13:886374. doi: 10.3389/fimmu.2022.886374
68. Chinju A, Moriyama M, Kakizoe-Ishiguro N, Chen H, Miyahara Y, Haque ASMR, et al. CD163+ M2 macrophages promote fibrosis in igG4-related disease via toll-like receptor 7/interleukin-1 receptor-associated kinase 4/NF-κB signaling. Arthritis Rheumatol Hoboken NJ. (2022) 74:892–901. doi: 10.1002/art.42043
69. Martín-Nares E, Hernández-Molina G, Priego-Ranero ÁA, Chan-Campos I, Herrera-Noguera GS, López-Verdugo F, et al. Peripheral immunophenotype in igG4-related disease and its association with clinical phenotypes and disease activity. Cells. (2023) 12:670. doi: 10.3390/cells12040670
70. Zhao W, Zhang H, Liu R, and Cui R. Advances in immunomodulatory mechanisms of mesenchymal stem cells-derived exosome on immune cells in scar formation. Int J Nanomed. (2023) 18:3643–62. doi: 10.2147/IJN.S412717
71. Liu X, Shao C, and Fu J. Promising biomarkers of radiation-induced lung injury: A review. Biomedicines. (2021) 9:1181. doi: 10.3390/biomedicines9091181
72. Clarkson TC, Iguchi N, Xie AX, and Malykhina AP. Differential transcriptomic changes in the central nervous system and urinary bladders of mice infected with a coronavirus. PloS One. (2022) 17:e0278918. doi: 10.1371/journal.pone.0278918
73. Aubert A, Jung K, Hiroyasu S, Pardo J, and Granville DJ. Granzyme serine proteases in inflammation and rheumatic diseases. Nat Rev Rheumatol. (2024) 20:361–76. doi: 10.1038/s41584-024-01109-5
74. Richardson KC, Jung K, Pardo J, Turner CT, and Granville DJ. Noncytotoxic roles of granzymes in health and disease. Physiol Bethesda Md. (2022) 37:323–48. doi: 10.1152/physiol.00011.2022
75. Motta J-P, Deraison C, Le Grand S, Le Grand B, and Vergnolle N. PAR-1 antagonism to promote gut mucosa healing in crohn’s disease patients: A new avenue for CVT120165. Inflammation Bowel Dis. (2021) 27:S33–7. doi: 10.1093/ibd/izab244
76. Chen H, Smith M, Herz J, Li T, Hasley R, Le Saout C, et al. The role of protease-activated receptor 1 signaling in CD8 T cell effector functions. iScience. (2021) 24:103387. doi: 10.1016/j.isci.2021.103387
77. Xu J, Zhai J, and Zhao J. Pathogenic roles of follicular helper T cells in IgG4-related disease and implications for potential therapy. Front Immunol. (2024) 15:1413860. doi: 10.3389/fimmu.2024.1413860
78. Murayama K, Ikegami I, Kamekura R, Sakamoto H, Yanagi M, Kamiya S, et al. CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions. Front Immunol. (2022) 13:941385. doi: 10.3389/fimmu.2022.941385
79. Newman JH, Shaver A, Sheehan JH, Mallal S, Stone JH, Pillai S, et al. IgG4-related disease: Association with a rare gene variant expressed in cytotoxic T cells. Mol Genet Genomic Med. (2019) 7:e686. doi: 10.1002/mgg3.686
80. Jurewicz MM and Stern LJ. Class II MHC antigen processing in immune tolerance and inflammation. Immunogenetics. (2019) 71:171–87. doi: 10.1007/s00251-018-1095-x
81. He L, Mei H, Gu Y, Liu Z, Yang L, Li X, et al. Combined impact of rituximab and target care on efficacy, quality of life, adverse reactions and recurrence rate in children with nephrotic syndrome: a randomized controlled trial. BMC Pediatr. (2025) 25:691. doi: 10.1186/s12887-025-06070-0
82. Zhuang J, Zhao Z, Zhang C, Song X, Lu C, Tian X, et al. Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia. Front Med. (2022) 9:1059740. doi: 10.3389/fmed.2022.1059740
83. Cieplińska K, Niedziela E, and Kowalska A. Immunological processes in the orbit and indications for current and potential drug targets. J Clin Med. (2023) 13:72. doi: 10.3390/jcm13010072
84. Yamamoto M. B cell targeted therapy for immunoglobulin G4-related disease. Immunol Med. (2021) 44:216–22. doi: 10.1080/25785826.2021.1886630
85. Pillai S. A twist in the tail: Of T cell subsets and disease. J Exp Med. (2023) 220:e20231423. doi: 10.1084/jem.20231423
86. D’Agostino GM, Rizzetto G, Marani A, Marasca S, Candelora M, Gambini D, et al. Bullous pemphygoid and novel therapeutic approaches. Biomedicines. (2022) 10:2844. doi: 10.3390/biomedicines10112844
87. Lin D-W, Chang C-C, Hsu Y-C, and Lin C-L. New insights into the treatment of glomerular diseases: when mechanisms become vivid. Int J Mol Sci. (2022) 23:3525. doi: 10.3390/ijms23073525
88. Kannan L. Rituximab for steroid-dependent minimal change disease in adults: is it time for a change? Cureus. (2022) 14:e22313. doi: 10.7759/cureus.22313
89. Farhangnia P, Ghomi SM, Mollazadehghomi S, Nickho H, Akbarpour M, and Delbandi A-A. SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. Front Immunol. (2023) 14:1174138. doi: 10.3389/fimmu.2023.1174138
90. Ishibashi M, Morita R, and Tamura H. Immune functions of signaling lymphocytic activation molecule family molecules in multiple myeloma. Cancers. (2021) 13:279. doi: 10.3390/cancers13020279
91. Lapietra G, Fazio F, and Petrucci MT. Race for the cure: from the oldest to the newest monoclonal antibodies for multiple myeloma treatment. Biomolecules. (2022) 12:1146. doi: 10.3390/biom12081146
92. Romano A, Storti P, Marchica V, Scandura G, Notarfranchi L, Craviotto L, et al. Mechanisms of action of the new antibodies in use in multiple myeloma. Front Oncol. (2021) 11:684561. doi: 10.3389/fonc.2021.684561
93. Chu E, Wu J, Kang SS, and Kang Y. SLAMF7 as a promising immunotherapeutic target in multiple myeloma treatments. Curr Oncol Tor Ont. (2023) 30:7891–903. doi: 10.3390/curroncol30090573
94. Dang QM, Watanabe R, Shiomi M, Fukumoto K, Nobashi TW, Okano T, et al. Rheumatic immune-related adverse events due to immune checkpoint inhibitors-A 2023 update. Int J Mol Sci. (2023) 24:5643. doi: 10.3390/ijms24065643
95. Chandrasekaran P, Krausz M, Han Y, Mitsuiki N, Gabrysch A, Nöltner C, et al. The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency. Microbiome. (2025) 13:51. doi: 10.1186/s40168-025-02028-7
96. Russell MA, Richardson SJ, and Morgan NG. The role of the interferon/JAK-STAT axis in driving islet HLA-I hyperexpression in type 1 diabetes. Front Endocrinol. (2023) 14:1270325. doi: 10.3389/fendo.2023.1270325
Keywords: CD4+ cytotoxic T lymphocytes, fibrosis, IgG4-related disease, immunopathogenesis, SLAMF7, tissue damage
Citation: Yi J, Jia L, Mao T and Li Z (2026) Beyond the Th2 paradigm: CD4+ cytotoxic T lymphocytes as key drivers of tissue damage and fibrosis in IgG4-related disease. Front. Immunol. 17:1781462. doi: 10.3389/fimmu.2026.1781462
Received: 05 January 2026; Accepted: 28 January 2026; Revised: 22 January 2026;
Published: 12 February 2026.
Edited by:
Gunnar Houen, University of Copenhagen, DenmarkReviewed by:
Chi Sing Ng, Hospital Authority, Hong Kong SAR, ChinaCopyright © 2026 Yi, Jia, Mao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhi Li, TGl6aGlAd25tYy5lZHUuY24=